Syneos Health, Inc. (NASDAQ: SYNH) Stock Competitors & Peer Comparison
See SYNH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SYNH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYNH | $42.98 | +0.02% | 4.5B | 61.40 | $0.70 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.72% |
| TMO | $613.62 | +0.62% | 228.1B | 26.50 | $23.16 | +0.29% |
| DHR | $203.25 | +1.55% | 142.9B | 25.48 | $7.98 | +0.72% |
| NTRA | $341.79 | +3.91% | 48.9B | -258.93 | -$1.32 | N/A |
| IQV | $265.67 | +1.49% | 43.7B | 21.91 | $12.13 | N/A |
| A | $146.80 | -0.09% | 41.5B | 25.27 | $5.81 | +0.69% |
| IDXX | $509.56 | +0.96% | 40.2B | 35.83 | $14.22 | N/A |
| ILMN | $208.21 | +0.85% | 31.5B | 41.39 | $5.03 | N/A |
| WAT | $410.01 | +0.41% | 30.7B | 29.97 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
SYNH vs DHR-PB Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, SYNH's ROE is +0.08%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, SYNH is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
SYNH vs TMO Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, TMO has a market cap of 228.1B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while TMO trades at $613.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas TMO's P/E ratio is 26.50. In terms of profitability, SYNH's ROE is +0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, SYNH is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
SYNH vs DHR Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, DHR has a market cap of 142.9B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while DHR trades at $203.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas DHR's P/E ratio is 25.48. In terms of profitability, SYNH's ROE is +0.08%, compared to DHR's ROE of +0.08%. Regarding short-term risk, SYNH is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
SYNH vs NTRA Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, NTRA has a market cap of 48.9B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while NTRA trades at $341.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas NTRA's P/E ratio is -258.93. In terms of profitability, SYNH's ROE is +0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, SYNH is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
SYNH vs IQV Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, IQV has a market cap of 43.7B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while IQV trades at $265.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas IQV's P/E ratio is 21.91. In terms of profitability, SYNH's ROE is +0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, SYNH is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
SYNH vs A Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, A has a market cap of 41.5B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while A trades at $146.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas A's P/E ratio is 25.27. In terms of profitability, SYNH's ROE is +0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, SYNH is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
SYNH vs IDXX Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, IDXX has a market cap of 40.2B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while IDXX trades at $509.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas IDXX's P/E ratio is 35.83. In terms of profitability, SYNH's ROE is +0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, SYNH is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
SYNH vs ILMN Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ILMN has a market cap of 31.5B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ILMN trades at $208.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ILMN's P/E ratio is 41.39. In terms of profitability, SYNH's ROE is +0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, SYNH is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
SYNH vs WAT Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, WAT has a market cap of 30.7B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while WAT trades at $410.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas WAT's P/E ratio is 29.97. In terms of profitability, SYNH's ROE is +0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, SYNH is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
SYNH vs DGX Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while DGX trades at $237.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas DGX's P/E ratio is 23.45. In terms of profitability, SYNH's ROE is +0.08%, compared to DGX's ROE of +0.14%. Regarding short-term risk, SYNH is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
SYNH vs MTD Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, MTD has a market cap of 26B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while MTD trades at $1,285.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas MTD's P/E ratio is 29.54. In terms of profitability, SYNH's ROE is +0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, SYNH is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
SYNH vs LH Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while LH trades at $315.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas LH's P/E ratio is 18.72. In terms of profitability, SYNH's ROE is +0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, SYNH is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
SYNH vs GH Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, GH has a market cap of 22.5B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while GH trades at $167.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas GH's P/E ratio is -48.09. In terms of profitability, SYNH's ROE is +0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, SYNH is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
SYNH vs EXAS Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas EXAS's P/E ratio is -95.37. In terms of profitability, SYNH's ROE is +0.08%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, SYNH is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
SYNH vs ILMNV Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ILMNV's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, SYNH is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
SYNH vs MEDP Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, MEDP has a market cap of 16.6B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while MEDP trades at $595.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas MEDP's P/E ratio is 34.90. In terms of profitability, SYNH's ROE is +0.08%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, SYNH is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
SYNH vs PKI Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas PKI's P/E ratio is 41.45. In terms of profitability, SYNH's ROE is +0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, SYNH is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
SYNH vs RVTY Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, RVTY has a market cap of 14.3B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while RVTY trades at $128.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas RVTY's P/E ratio is 24.02. In terms of profitability, SYNH's ROE is +0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, SYNH is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
SYNH vs CRL Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CRL trades at $273.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CRL's P/E ratio is 27.58. In terms of profitability, SYNH's ROE is +0.08%, compared to CRL's ROE of -0.08%. Regarding short-term risk, SYNH is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
SYNH vs ICLR Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ICLR has a market cap of 12.9B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ICLR trades at $168.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ICLR's P/E ratio is 13.78. In terms of profitability, SYNH's ROE is +0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, SYNH is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
SYNH vs QGEN Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, QGEN has a market cap of 8.6B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while QGEN trades at $41.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas QGEN's P/E ratio is 17.30. In terms of profitability, SYNH's ROE is +0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, SYNH is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
SYNH vs RDNT Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, RDNT has a market cap of 5.9B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while RDNT trades at $75.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas RDNT's P/E ratio is 164.11. In terms of profitability, SYNH's ROE is +0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, SYNH is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
SYNH vs SHC Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while SHC trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas SHC's P/E ratio is 19.29. In terms of profitability, SYNH's ROE is +0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, SYNH is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
SYNH vs BLLN Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BLLN trades at $100.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BLLN's P/E ratio is 144.03. In terms of profitability, SYNH's ROE is +0.08%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, SYNH is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BLLN's competition here
Veracyte, Inc. (NASDAQ: VCYT)
SYNH vs VCYT Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while VCYT trades at $41.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas VCYT's P/E ratio is 20.61. In terms of profitability, SYNH's ROE is +0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, SYNH is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
SYNH vs OLK Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas OLK's P/E ratio is -96.59. In terms of profitability, SYNH's ROE is +0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, SYNH is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check OLK's competition here
GRAIL Inc. (NASDAQ: GRAL)
SYNH vs GRAL Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, GRAL has a market cap of 3.2B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while GRAL trades at $75.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas GRAL's P/E ratio is -7.75. In terms of profitability, SYNH's ROE is +0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, SYNH is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check GRAL's competition here
CareDx, Inc (NASDAQ: CDNA)
SYNH vs CDNA Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CDNA trades at $52.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CDNA's P/E ratio is 62.35. In terms of profitability, SYNH's ROE is +0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, SYNH is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check CDNA's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
SYNH vs WGS Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, WGS has a market cap of 2.7B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while WGS trades at $89.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas WGS's P/E ratio is 249.28. In terms of profitability, SYNH's ROE is +0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, SYNH is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
SYNH vs PSNL Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while PSNL trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas PSNL's P/E ratio is -14.94. In terms of profitability, SYNH's ROE is +0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, SYNH is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
SYNH vs OPK Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while OPK trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas OPK's P/E ratio is -5.78. In terms of profitability, SYNH's ROE is +0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, SYNH is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
SYNH vs CSTL Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CSTL trades at $33.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CSTL's P/E ratio is -50.67. In terms of profitability, SYNH's ROE is +0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, SYNH is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
SYNH vs FLGT Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, FLGT has a market cap of 586.5M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while FLGT trades at $20.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas FLGT's P/E ratio is 2065.00. In terms of profitability, SYNH's ROE is +0.08%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, SYNH is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
SYNH vs GRALV Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas GRALV's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, SYNH is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
SYNH vs NEO Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, NEO has a market cap of 473M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while NEO trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas NEO's P/E ratio is 141.62. In terms of profitability, SYNH's ROE is +0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, SYNH is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
SYNH vs CO Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CO's P/E ratio is 5.06. In terms of profitability, SYNH's ROE is +0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, SYNH is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
SYNH vs MYGN Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, MYGN has a market cap of 358M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while MYGN trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas MYGN's P/E ratio is -29.15. In terms of profitability, SYNH's ROE is +0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, SYNH is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check MYGN's competition here
Prenetics Global Limited (NASDAQ: PRENW)
SYNH vs PRENW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, PRENW has a market cap of 303.1M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas PRENW's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, SYNH is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check PRENW's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
SYNH vs FLDM Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas FLDM's P/E ratio is -4.74. In terms of profitability, SYNH's ROE is +0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, SYNH is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
SYNH vs BDSX Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BDSX has a market cap of 223M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BDSX trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BDSX's P/E ratio is -8.64. In terms of profitability, SYNH's ROE is +0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, SYNH is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
SYNH vs XGN Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, XGN has a market cap of 177.6M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while XGN trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas XGN's P/E ratio is -9.07. In terms of profitability, SYNH's ROE is +0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, SYNH is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
SYNH vs IMDX Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while IMDX trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas IMDX's P/E ratio is -2.70. In terms of profitability, SYNH's ROE is +0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, SYNH is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
SYNH vs GTH Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas GTH's P/E ratio is -1.11. In terms of profitability, SYNH's ROE is +0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, SYNH is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
SYNH vs GENE Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas GENE's P/E ratio is -38.25. In terms of profitability, SYNH's ROE is +0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, SYNH is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
SYNH vs SERA Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, SERA has a market cap of 76.4M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas SERA's P/E ratio is -3.08. In terms of profitability, SYNH's ROE is +0.08%, compared to SERA's ROE of -0.47%. Regarding short-term risk, SYNH is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
SYNH vs PRPO Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while PRPO trades at $27.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas PRPO's P/E ratio is -104.73. In terms of profitability, SYNH's ROE is +0.08%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, SYNH is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
SYNH vs MDXH Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, MDXH has a market cap of 36.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while MDXH trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas MDXH's P/E ratio is -1.86. In terms of profitability, SYNH's ROE is +0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, SYNH is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
SYNH vs QUCY Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, QUCY has a market cap of 30.1M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas QUCY's P/E ratio is -0.06. In terms of profitability, SYNH's ROE is +0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, SYNH is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
SYNH vs AKU Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas AKU's P/E ratio is -0.13. In terms of profitability, SYNH's ROE is +0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, SYNH is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
SYNH vs CEMI Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CEMI's P/E ratio is -0.63. In terms of profitability, SYNH's ROE is +0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, SYNH is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
SYNH vs ENZ Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ENZ's P/E ratio is -2.24. In terms of profitability, SYNH's ROE is +0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, SYNH is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
SYNH vs PMD Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas PMD's P/E ratio is -5.24. In terms of profitability, SYNH's ROE is +0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, SYNH is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
SYNH vs ME Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ME's P/E ratio is -0.03. In terms of profitability, SYNH's ROE is +0.08%, compared to ME's ROE of -42.03%. Regarding short-term risk, SYNH is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
SYNH vs MYNZ Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, SYNH's ROE is +0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, SYNH is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
SYNH vs BNR Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BNR has a market cap of 12.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BNR trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BNR's P/E ratio is -13.33. In terms of profitability, SYNH's ROE is +0.08%, compared to BNR's ROE of -0.11%. Regarding short-term risk, SYNH is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
SYNH vs CHEK Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CHEK's P/E ratio is -0.43. In terms of profitability, SYNH's ROE is +0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, SYNH is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check CHEK's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
SYNH vs ADVB Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ADVB has a market cap of 10.8M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ADVB trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ADVB's P/E ratio is -70.73. In terms of profitability, SYNH's ROE is +0.08%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, SYNH is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check ADVB's competition here
Centogene N.V. (NASDAQ: CNTG)
SYNH vs CNTG Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CNTG's P/E ratio is -0.23. In terms of profitability, SYNH's ROE is +0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, SYNH is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
SYNH vs NDRA Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while NDRA trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas NDRA's P/E ratio is -0.76. In terms of profitability, SYNH's ROE is +0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, SYNH is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
SYNH vs APDN Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas APDN's P/E ratio is -0.10. In terms of profitability, SYNH's ROE is +0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, SYNH is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check APDN's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
SYNH vs BIAFW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BIAFW has a market cap of 6.4M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BIAFW's P/E ratio is 0.68. In terms of profitability, SYNH's ROE is +0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, SYNH is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
SYNH vs NVTA Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas NVTA's P/E ratio is -0.00. In terms of profitability, SYNH's ROE is +0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, SYNH is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
SYNH vs LMDXW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, SYNH's ROE is +0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, SYNH is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
SYNH vs LMDX Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas LMDX's P/E ratio is -0.01. In terms of profitability, SYNH's ROE is +0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, SYNH is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
SYNH vs BIAF Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BIAF's P/E ratio is -0.93. In terms of profitability, SYNH's ROE is +0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, SYNH is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
SYNH vs DMTK Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas DMTK's P/E ratio is -0.04. In terms of profitability, SYNH's ROE is +0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, SYNH is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
SYNH vs NOTV Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas NOTV's P/E ratio is -0.03. In terms of profitability, SYNH's ROE is +0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, SYNH is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
SYNH vs SQL Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas SQL's P/E ratio is -0.40. In terms of profitability, SYNH's ROE is +0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, SYNH is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
SYNH vs AWH Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas AWH's P/E ratio is -0.09. In terms of profitability, SYNH's ROE is +0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, SYNH is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
SYNH vs HTGM Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas HTGM's P/E ratio is -0.03. In terms of profitability, SYNH's ROE is +0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, SYNH is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
SYNH vs BIOC Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BIOC's P/E ratio is -0.01. In terms of profitability, SYNH's ROE is +0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, SYNH is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
SYNH vs ISPC Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, ISPC has a market cap of 204.1K. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while ISPC trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas ISPC's P/E ratio is -0.05. In terms of profitability, SYNH's ROE is +0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, SYNH is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
SYNH vs SQLLW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, SYNH's ROE is +0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, SYNH is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
SYNH vs WGSWW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, SYNH's ROE is +0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, SYNH is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
SYNH vs DHR-PA Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, SYNH's ROE is +0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, SYNH is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
SYNH vs PRXL Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas PRXL's P/E ratio is 42.97. In terms of profitability, SYNH's ROE is +0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, SYNH is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for SYNH.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
SYNH vs NDRAW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas NDRAW's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, SYNH is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
SYNH vs CHEKZ Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, SYNH is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
SYNH vs OCDX Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas OCDX's P/E ratio is -42.28. In terms of profitability, SYNH's ROE is +0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, SYNH is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
SYNH vs BNGOW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas BNGOW's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, SYNH is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check BNGOW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
SYNH vs MEUSW Comparison September 2026
Syneos Health, Inc. (NASDAQ: SYNH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNH stands at 4.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, SYNH is priced at $42.98 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNH currently has a P/E ratio of 61.40, whereas MEUSW's P/E ratio is N/A. In terms of profitability, SYNH's ROE is +0.08%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, SYNH is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for SYNH.Check MEUSW's competition here